Table 1.
PD patient and control demographics
| Control | PD | p | |
|---|---|---|---|
| Sample size | 63 | 61 | – |
| Sex (% male) | 51% | 66% | 0.105 |
| Age at visit | 67.5 (7.2) | 67.4 (7.1) | 0.957 |
| CMV (% positive) | 44% | 48% | 0.719 |
| EBV (% positive) | 92% | 85% | 0.267 |
| ACE-III | 94.1 (7.4) | 93.0 (4.5) | 0.011* |
| Disease duration (years) | – | 0.97 (0.54) | – |
| MDS-UPDRS-III (motor score) | – | 27.8 (10.3) | – |
| MDS-UPDRS total | – | 47.4 (15.1) | – |
| Levodopa equivalent daily-dose (LEDD) | – | 290 (163.5) | – |
CMV, Cytomegalovirus; EBV, Epstein–Barr virus; ACE-III, Addenbrooke’s cognitive examination III; MDS-UPDRS, Movement Disorder Society—Unified Parkinson’s Disease Rating Scale (measured on medication). ACE-III was done in all PD patients and a subset of 41 controls. The values represent the mean (SD); *p < 0.05